<DOC>
	<DOCNO>NCT00078845</DOCNO>
	<brief_summary>RATIONALE : Amifostine may effective reduce pain , numbness , tingle , symptoms peripheral neuropathy . PURPOSE : This phase II trial study well amifostine work reduce pain , numbness , tingle , symptoms peripheral neuropathy patient receive paclitaxel solid tumor .</brief_summary>
	<brief_title>Amifostine Treating Peripheral Neuropathy Caused Paclitaxel Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine percentage patient solid tumor persistent paclitaxel-induced peripheral neuropathy benefit , define decrease least 20 % FUNCTIONAL ASSESSMENT OF CANCER THERAPY/ GYNECOLOGIC ONCOLOGY GROUP NEUROTOXICITY ( FACT/GOG-Ntx ) FACT-GOG-NTX score , treatment subcutaneous amifostine . - Determine whether sufficient evidence reversal activity drug patient justify phase III study . Secondary - Compare acute toxic effect drug administer subcutaneously patient vs IV administration drug historically and/or GOG-0192 study . - Determine capability Weinstein Enhanced Sensory Test provide objective , quantitative evidence improvement patient subjective improvement self-reported FACT-GOG-NTX scale . - Determine whether benefit patient treat drug transient last least 8 week . OUTLINE : This open-label , multicenter study . Patients receive amifostine subcutaneously three time weekly 4 week absence symptom progression unacceptable toxicity . Patients achieve complete partial response receive additional 4 week therapy . Neuropathy symptom assess use FACT-GOG-NTX questionnaire administer baseline , weekly therapy , 12 week Weinstein Enhanced Sensory Test administer baseline 4 , 8 , 12 week . Patients follow 12 week . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 10-20 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis solid tumor , include , limited following : Ovarian cancer Lung cancer Prostate cancer Breast cancer Previously treat paclitaxel Peripheral neuropathy ( e.g. , numbness , tingle , and/or pain distal extremity ) believe cause paclitaxel combination paclitaxel carboplatin At least 18 44 FACTGOGNTX scale Persistent neuropathy least 2 , 12 month chemotherapy Not improve No possible cause neuropathy ( e.g. , alcoholism , diabetes , peripheral vascular disease ) Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status Karnofsky 50100 % Life expectancy More 2 month Hematopoietic Not specify Hepatic Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Calcium ≥ low limit normal Cardiovascular See Disease Characteristics No prior cerebrovascular accident Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No significant comorbid medical condition would preclude study participation No known sensitivity aminothiol compound PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No prior cisplatin No chemotherapy least 3 month study participation Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No concurrent monoamine oxidase inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage I non-small cell lung cancer</keyword>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage I ovarian epithelial cancer</keyword>
	<keyword>stage II ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>